Last quarter (Q2 2023), SkinBioTherapeutics's total revenue was £―, a decrease of ― from the same quarter last year. In Q2, SkinBioTherapeutics's net income was £―. See SkinBioTherapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Jun 22	Jun 21	Jun 20	Jun 19	Jun 18
Total Revenue	-	£ 74.76K	-	£ 0.00	£ 0.00	-
Cost of Revenue	-	£ 29.42K	-	-	-	-
Gross Profit	-	£ 45.34K	-	-	-	-
Operating Expense	-	£ 2.76M	£ 1.49M	£ 1.62M	£ 1.36M	£ 941.38K
Operating Income	-	£ -2.71M	£ -1.49M	£ -1.62M	£ -1.36M	£ -941.38K
Net Non Operating Interest Income Expense	-	£ -10.13K	£ 926.00	£ 0.00	£ 0.00	£ 0.00
Other Income Expense	-	£ 267.19K	-	-	-	-
Pretax Income	-	£ -2.99M	£ -1.50M	£ -1.62M	£ -1.36M	£ -941.45K
Tax Provision	-	£ -199.62K	£ -65.06K	£ -119.96K	£ -212.39K	£ -97.03K
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	-	£ -2.79M	£ -1.43M	£ -1.50M	£ -1.15M	£ -844.42K
Basic EPS	-	£ -0.02	£ -0.01	£ -0.01	£ >-0.01	£ >-0.01
Diluted EPS	-	£ -0.02	£ -0.01	£ -0.01	£ >-0.01	£ >-0.01
Basic Average Shares	-	£ 156.78M	£ 146.70M	£ 128.08M	£ 122.37M	£ 118.71M
Diluted Average Shares	-	£ 156.78M	£ 146.70M	£ 128.08M	£ 122.37M	£ 118.71M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	-	£ 2.79M	£ -1.49M	£ 1.62M	£ 1.36M	£ 941.38K
Net Income From Continuing And Discontinued Operation	-	£ -2.79M	£ -1.43M	£ -1.50M	£ -1.15M	£ -844.42K
Normalized Income	-	£ -2.93M	£ -1.56M	£ -1.50M	£ -1.15M	£ -844.42K
Interest Expense	-	-	-	£ 0.00	£ 0.00	£ 0.00
EBIT	-	£ -2.98M	£ -1.50M	£ -1.62M	£ -1.36M	£ -941.45K
EBITDA	-	£ -2.94M	£ -1.50M	£ -1.61M	£ -1.36M	£ -941.45K

Currency in GBP

SkinBioTherapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing